BioScrip Company Profile (NASDAQ:BIOS)

About BioScrip (NASDAQ:BIOS)

BioScrip logoBioScrip, Inc. is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment. The Company operates through approximately 70 service locations in over 30 states. The Company offers home infusion services to provide clinical management services and the delivery of prescription medications. The Company provides services in coordination with, and under the direction of, the patient's physician. The Company's multidisciplinary team of clinicians, including pharmacists, nurses, dietitians and respiratory therapists, work with the physician to develop a plan of care suited to the patient's specific needs. Its platform provides service capabilities to deliver clinical management services that offer patients a community-based and home-based care environment.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Hospitals, Clinics & Primary Care Services
  • Sub-Industry: Health Care Services
  • Symbol: NASDAQ:BIOS
  • CUSIP: 09069N10
  • Web:
  • Market Cap: $342.91 million
  • Outstanding Shares: 127,475,000
Average Prices:
  • 50 Day Moving Avg: $2.86
  • 200 Day Moving Avg: $2.29
  • 52 Week Range: $0.98 - $3.43
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -15.94
  • P/E Growth: -0.49
Sales & Book Value:
  • Annual Revenue: $900.58 million
  • Price / Sales: 0.36
  • Book Value: ($0.50) per share
  • Price / Book: -5.10
  • EBIDTA: $25.07 million
  • Net Margins: -8.03%
  • Return on Assets: -7.39%
  • Debt-to-Equity Ratio: -7.49%
  • Current Ratio: 1.85%
  • Quick Ratio: 1.57%
  • Average Volume: 1.54 million shs.
  • Beta: 0.28
  • Short Ratio: 21.49

Frequently Asked Questions for BioScrip (NASDAQ:BIOS)

What is BioScrip's stock symbol?

BioScrip trades on the NASDAQ under the ticker symbol "BIOS."

How were BioScrip's earnings last quarter?

BioScrip, Inc. (NASDAQ:BIOS) posted its earnings results on Tuesday, August, 8th. The company reported ($0.11) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.10) by $0.01. The firm had revenue of $218.11 million for the quarter, compared to analysts' expectations of $220.05 million. The company's revenue for the quarter was down 6.2% on a year-over-year basis. During the same period last year, the company posted ($0.14) earnings per share. View BioScrip's Earnings History.

When will BioScrip make its next earnings announcement?

BioScrip is scheduled to release their next quarterly earnings announcement on Monday, November, 6th 2017. View Earnings Estimates for BioScrip.

Where is BioScrip's stock going? Where will BioScrip's stock price be in 2017?

4 brokers have issued twelve-month price objectives for BioScrip's stock. Their predictions range from $3.50 to $4.50. On average, they anticipate BioScrip's stock price to reach $3.94 in the next twelve months. View Analyst Ratings for BioScrip.

What are analysts saying about BioScrip stock?

Here are some recent quotes from research analysts about BioScrip stock:

  • 1. According to Zacks Investment Research, "BioScrip exited the second quarter on a dismal note with revenues missing the Zacks Consensus Estimate and adjusted net loss wider-than-expected. Management’s unimpressive 2017 guidance, which includes the negative impact of the Cures Act legislation, also adds to our concerns. Nonetheless, the market is upbeat about BioScrip’s announcement to continue to offer certain core product lines to UnitedHealthcare. We are encouraged by the company’s recent progress, courtesy of its new multi-faceted CORE plan which was adopted to improve the financial position. Further, the company achieved annualized supply chain improvement of roughly $20 million since the acquisition of Home Solutions. Over the last three months, BioScrip has been trading above the broader industry." (8/14/2017)
  • 2. Jefferies Group LLC analysts commented, "We are incrementally more positive on BIOS following better-than-expected 4Q results. Growth in Core revenues is progressing according to plan & expense initiatives should offset a majority of the headwind from the 21st Century Cures Act. Accelerating EBITDA growth throughout 2017 should provide investors with increasing confidence in BIOS ability to reduce debt leverage to more normalized levels (~6x) by YE17 & put BIOS on a path to >$80MM of EBITDA in 2018." (3/6/2017)

Are investors shorting BioScrip?

BioScrip saw a decrease in short interest in August. As of August 31st, there was short interest totalling 18,783,163 shares, a decrease of 11.6% from the August 15th total of 21,241,640 shares. Based on an average daily volume of 2,028,727 shares, the short-interest ratio is currently 9.3 days. Approximately 14.8% of the shares of the company are sold short.

Who are some of BioScrip's key competitors?

Who are BioScrip's key executives?

BioScrip's management team includes the folowing people:

  • Daniel E. Greenleaf, President, Chief Executive Officer, Director
  • Stephen M. Deitsch, Chief Financial Officer, Senior Vice President, Treasurer
  • David Evans, Chief Operating Officer, Senior Vice President
  • Betty Y Jang, Senior Vice President, Chief Compliance Officer
  • C. Britt Jeffcoat, Chief Accounting Officer, Vice President, Controller
  • Kathryn M. Stalmack, General Counsel
  • Scott J. Davido, Chief Implementation Officer
  • Michael G. Bronfein CPA, Director
  • Steven Neumann, Director
  • Christopher S. Shackelton, Director

Who owns BioScrip stock?

BioScrip's stock is owned by a number of of retail and institutional investors. Top institutional investors include COLISEUM CAPITAL MANAGEMENT, LLC (16.50%), COLISEUM CAPITAL MANAGEMENT, LLC (14.60%), Gilder Gagnon Howe & Co. LLC (12.57%), GAMCO INVESTORS, INC. ET AL (10.37%), ARES MANAGEMENT LLC (9.20%) and GAMCO INVESTORS, INC. ET AL (9.19%). Company insiders that own BioScrip stock include Coliseum Capital Management, L, Daniel E Greenleaf, David W Golding, Jeffrey M Kreger, Michael G Bronfein and R Carter Pate. View Institutional Ownership Trends for BioScrip.

Who sold BioScrip stock? Who is selling BioScrip stock?

BioScrip's stock was sold by a variety of institutional investors in the last quarter, including Diamond Hill Capital Management Inc., Perkins Capital Management Inc., Virtu KCG Holdings LLC, California Public Employees Retirement System, Gamco Investors INC. ET AL, Marathon Capital Management, California State Teachers Retirement System and Parametric Portfolio Associates LLC. Company insiders that have sold BioScrip stock in the last year include Coliseum Capital Management, L and Michael G Bronfein. View Insider Buying and Selling for BioScrip.

Who bought BioScrip stock? Who is buying BioScrip stock?

BioScrip's stock was purchased by a variety of institutional investors in the last quarter, including Gilder Gagnon Howe & Co. LLC, Alta Fundamental Advisers LLC, FMR LLC, Roanoke Asset Management Corp NY, State Street Corp, Vanguard Group Inc., Benchmark Capital Advisors and Northern Trust Corp. Company insiders that have bought BioScrip stock in the last two years include Coliseum Capital Management, L, Daniel E Greenleaf, David W Golding, Jeffrey M Kreger and R Carter Pate. View Insider Buying and Selling for BioScrip.

How do I buy BioScrip stock?

Shares of BioScrip can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is BioScrip's stock price today?

One share of BioScrip stock can currently be purchased for approximately $2.55.

MarketBeat Community Rating for BioScrip (NASDAQ BIOS)
Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  143 (Vote Outperform)
Underperform Votes:  95 (Vote Underperform)
Total Votes:  238
MarketBeat's community ratings are surveys of what our community members think about BioScrip and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for BioScrip (NASDAQ:BIOS) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 4 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $3.94 (54.41% upside)

Analysts' Ratings History for BioScrip (NASDAQ:BIOS)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/10/2017SunTrust Banks, Inc.UpgradeHold -> Buy$3.25 -> $3.75HighView Rating Details
8/10/2017Jefferies Group LLCReiterated RatingBuy$3.00 -> $4.00HighView Rating Details
6/26/2017Barrington ResearchBoost Price TargetOutperform$3.50HighView Rating Details
1/3/2017Lake Street CapitalInitiated CoverageBuy$4.50N/AView Rating Details
3/5/2016StephensReiterated RatingBuyN/AView Rating Details
(Data available from 9/20/2015 forward)


Earnings History for BioScrip (NASDAQ:BIOS)
Earnings by Quarter for BioScrip (NASDAQ:BIOS)
Earnings History by Quarter for BioScrip (NASDAQ BIOS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/6/2017($0.10)N/AView Earnings Details
8/8/2017Q2 2017($0.10)($0.11)$220.05 million$218.11 millionViewListenView Earnings Details
5/4/2017Q1 2017($0.12)($0.16)$230.23 million$217.80 millionViewListenView Earnings Details
3/3/2017Q4 2016($0.08)($0.08)$236.67 million$240.10 millionViewListenView Earnings Details
11/7/2016Q3($0.05)($0.12)$223.26 million$224.50 millionViewListenView Earnings Details
8/8/2016Q216($0.09)($0.08)$229.58 million$232.50 millionViewListenView Earnings Details
5/5/2016Q1($0.12)($0.17)$232.38 million$238.50 millionViewListenView Earnings Details
3/2/2016Q4($0.08)($0.13)$238.30 million$243.75 millionViewListenView Earnings Details
11/4/2015Q315($0.10)($0.19)$229.89 million$247.20 millionViewListenView Earnings Details
8/10/2015Q215($0.11)($0.02)$269.38 million$262.40 millionViewListenView Earnings Details
5/7/2015Q115($0.08)($0.19)$259.60 million$261.70 millionViewListenView Earnings Details
3/2/2015Q414($0.02)($0.72)$259.62 million$253.70 millionViewListenView Earnings Details
11/5/2014Q314$0.02($0.45)$240.08 million$244.00 millionViewListenView Earnings Details
8/6/2014Q214($0.05)($0.10)$233.70 million$247.10 millionViewListenView Earnings Details
5/8/2014Q114($0.04)($0.17)$222.65 million$239.60 millionViewListenView Earnings Details
2/26/2014Q413$0.02$0.02$237.58 million$243.50 millionViewListenView Earnings Details
8/7/2013Q2 2013$0.04$0.13$206.47 million$190.73 millionViewListenView Earnings Details
5/8/2013Q1 2013$0.02$0.04$189.36 million$199.07 millionViewListenView Earnings Details
3/11/2013Q4 2012$0.01$0.04$173.87 million$180.70 millionViewListenView Earnings Details
11/7/2012Q312($0.01)($0.01)$159.86 million$170.36 millionViewN/AView Earnings Details
8/8/2012($0.01)($0.07)ViewN/AView Earnings Details
5/9/2012($0.01)($0.05)ViewN/AView Earnings Details
3/9/2012$0.09$0.12ViewN/AView Earnings Details
11/8/2011$0.09$0.10ViewN/AView Earnings Details
8/8/2011$0.08$0.10ViewN/AView Earnings Details
5/3/2011($0.01)$0.05ViewN/AView Earnings Details
3/11/2011$0.04($1.25)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for BioScrip (NASDAQ:BIOS)
2017 EPS Consensus Estimate: ($0.27)
2018 EPS Consensus Estimate: ($0.23)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173($0.14)($0.08)($0.12)
Q2 20172($0.10)($0.06)($0.08)
Q3 20173($0.08)($0.04)($0.06)
Q4 20173($0.03)$0.00($0.02)
Q1 20181($0.10)($0.10)($0.10)
Q2 20181($0.07)($0.07)($0.07)
Q3 20181($0.06)($0.06)($0.06)
Q4 20181$0.00$0.00$0.00
(Data provided by Zacks Investment Research)


Dividend History for BioScrip (NASDAQ:BIOS)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for BioScrip (NASDAQ:BIOS)
Insider Ownership Percentage: 0.80%
Institutional Ownership Percentage: 84.05%
Insider Trades by Quarter for BioScrip (NASDAQ:BIOS)
Institutional Ownership by Quarter for BioScrip (NASDAQ:BIOS)
Insider Trades by Quarter for BioScrip (NASDAQ:BIOS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/15/2017Michael G BronfeinDirectorSell27,000$2.69$72,630.00View SEC Filing  
9/7/2017Coliseum Capital Management, LDirectorSell2,846,941$2.93$8,341,537.13View SEC Filing  
8/17/2017Coliseum Capital Management, LDirectorSell886,478$3.08$2,730,352.24View SEC Filing  
11/11/2016Jeffrey M KregerCFOBuy10,000$1.32$13,200.00View SEC Filing  
11/10/2016Daniel E GreenleafCEOBuy16,000$1.30$20,800.00View SEC Filing  
11/10/2016R Carter PateDirectorBuy20,000$1.30$26,000.00View SEC Filing  
6/22/2016Coliseum Capital Management, LDirectorBuy4,200,000$2.00$8,400,000.00View SEC Filing  
6/17/2016David W GoldingDirectorBuy12,500$2.48$31,000.00View SEC Filing  
8/24/2015Coliseum Capital Management, LDirectorBuy789,503$1.88$1,484,265.64View SEC Filing  
8/21/2015Coliseum Capital Management, LDirectorBuy632,907$1.81$1,145,561.67View SEC Filing  
8/18/2015David W GoldingDirectorBuy20,000$1.54$30,800.00View SEC Filing  
3/16/2015Richard M SmithCEOBuy5,000$4.27$21,350.00View SEC Filing  
3/12/2015Yon JordenDirectorBuy5,000$3.47$17,350.00View SEC Filing  
6/16/2014Myron Z HolubiakDirectorSell5,000$7.94$39,700.00View SEC Filing  
5/14/2014Yon JordenDirectorBuy5,000$7.21$36,050.00View SEC Filing  
8/30/2013Daniel ColucciVPSell18,500$12.40$229,400.00View SEC Filing  
8/28/2013David HubersDirectorSell11,200$12.23$136,976.00View SEC Filing  
8/28/2013Patricia BoguszVPSell39,687$11.94$473,862.78View SEC Filing  
8/19/2013Kohlberg Management V, LlcInsiderSell6,895,873$13.00$89,646,349.00View SEC Filing  
7/19/2013Myron Z HolubiakDirectorSell31,200$16.34$509,808.00View SEC Filing  
11/13/2012Stuart A SamuelsDirectorSell11,200$9.66$108,192.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for BioScrip (NASDAQ:BIOS)
Latest Headlines for BioScrip (NASDAQ:BIOS)
DateHeadline logoBioScrip, Inc. (BIOS) Given Average Rating of "Hold" by Analysts - September 20 at 4:44 AM logoBioScrip, Inc. (BIOS) Director Sells $72,630.00 in Stock - September 19 at 4:28 PM logo Brokerages Expect BioScrip, Inc. (BIOS) to Announce -$0.10 Earnings Per Share - September 19 at 2:18 AM logoHead to Head Survey: AMN Healthcare Services (AMN) and BioScrip (BIOS) - September 17 at 6:38 PM logoBioScrip, Inc. (BIOS) Sees Significant Decline in Short Interest - September 15 at 1:28 AM logoHealthways (TVTY) vs. BioScrip (BIOS) Head-To-Head Analysis - September 12 at 10:24 PM logoBioScrip: Cost Cuts and Potential Legislation Sparks Analyst Coverage - September 12 at 4:50 PM logoBRIEF-Coliseum Capital reports 14.6 pct stake in Bioscrip - September 8 at 4:57 PM logoBioScrip, Inc. (BIOS) Director Sells $8,341,537.13 in Stock - September 7 at 10:22 PM logoAMN Healthcare Services (AMN) & BioScrip (BIOS) Critical Comparison - September 6 at 12:16 AM logoBioScrip, Inc. (BIOS) Expected to Announce Quarterly Sales of $203.04 Million - September 2 at 8:06 AM logoBioScrip's Infusion Business Strong, Dull 2017 View a Drag (Revised) - September 1 at 4:53 PM logoHealthways (TVTY) & BioScrip (BIOS) Financial Contrast - September 1 at 6:06 AM logoBioScrip, Inc. – Value Analysis (NASDAQ:BIOS) : August 30, 2017 - August 30 at 2:59 AM logoReviewing BioScrip (BIOS) and AMN Healthcare Services (AMN) - August 27 at 2:28 AM logoBioScrip, Inc. (BIOS) Receives Average Rating of "Hold" from Brokerages - August 26 at 4:12 AM
News IconUS Bioservices to resolve kickback claims for $13.4 mln -filing ... - Business Insider - August 24 at 2:49 AM logoBioScrip, Inc. breached its 50 day moving average in a Bearish Manner : BIOS-US : August 23, 2017 - August 23 at 4:43 PM logoBioScrip Inc (BIOS) Downgraded by ValuEngine - August 22 at 10:36 PM logoBioScrip's Infusion Business Strong, Dull 2017 View a Drag - August 21 at 9:33 PM logoBioScrip's Infusion Business Strong, Dull 2017 View a Drag - Nasdaq - August 21 at 4:30 PM logoBidaskClub Lowers BioScrip, Inc. (BIOS) to Hold - August 20 at 2:32 PM logoColiseum Capital Management, L Sells 886,478 Shares of BioScrip, Inc. (BIOS) Stock - August 17 at 10:27 PM logo$205.29 Million in Sales Expected for BioScrip, Inc. (BIOS) This Quarter - August 15 at 3:28 PM logoZacks Investment Research Lowers BioScrip, Inc. (BIOS) to Hold - August 14 at 3:21 PM logoFY2017 EPS Estimates for BioScrip, Inc. Increased by Analyst (NASDAQ:BIOS) - August 14 at 5:52 AM logoBarrington Research Equities Analysts Boost Earnings Estimates for BioScrip, Inc. (NASDAQ:BIOS) - August 14 at 3:36 AM logoBioScrip (BIOS) Shows Strength: Stock Adds 6.6% in Session - August 11 at 5:00 PM logoBioScrip, Inc. (NASDAQ:BIOS) Receives Buy Rating from Jefferies Group LLC - August 10 at 2:16 PM logoBioScrip, Inc. (BIOS) Releases Earnings Results, Misses Expectations By $0.01 EPS - August 9 at 10:05 PM logoBioScrip (BIOS) Q2 Loss Wider Than Expected, Revenues Miss - August 9 at 4:46 PM logoEdited Transcript of BIOS earnings conference call or presentation 8-Aug-17 1:00pm GMT - August 9 at 2:42 AM logoBioScrip Reports Second Quarter 2017 Financial Results Nasdaq ... - GlobeNewswire (press release) - August 8 at 4:20 PM logoBRIEF-BioScrip qtrly loss per share $0.26 - Reuters - August 8 at 4:20 PM logoBioScrip Reports Second Quarter 2017 Financial Results - August 8 at 4:20 PM logoBioScrip reports 2Q loss - August 8 at 4:20 PM logoBioScrip, Inc. -- Moody's rates BioScrip's new debt; Caa2 CFR affirmed - August 1 at 5:25 PM logoBioScrip, Inc. (BIOS) Receives Average Rating of "Buy" from Analysts - August 1 at 9:23 AM logoBioScrip, Inc. (BIOS) Scheduled to Post Quarterly Earnings on Monday - July 31 at 8:11 AM logoFirst Choice Appoints New CFO to Help Lead Company Through Next Phase of Strategic Execution - July 27 at 5:03 PM logoBioScrip, Inc. (BIOS) Expected to Announce Quarterly Sales of $219.72 Million - July 27 at 11:21 AM logoBioScrip Applauds US House Passage of HR3178, the Medicare Part B Improvement Act of 2017 - GlobeNewswire (press release) - July 26 at 5:08 PM logoBioScrip Applauds US House Passage of HR3178, the Medicare Part B Improvement Act of 2017 - July 26 at 5:08 PM logo-$0.10 EPS Expected for BioScrip, Inc. (NASDAQ:BIOS) This Quarter - July 26 at 12:27 AM logoRoanoke Asset Management Corp Buys Emerson Electric Co, Eli Lilly and Co, Fortive Corp, Sells ... - July 20 at 6:10 PM logoBioScrip To Host Second Quarter Results Call - GlobeNewswire (press release) - July 17 at 4:50 PM logoBioScrip To Host Second Quarter Results Call - July 17 at 4:50 PM logoBioScrip, Inc. (BIOS) Upgraded to "Hold" at ValuEngine - July 16 at 5:14 PM logoBioScrip, Inc. (BIOS) Upgraded to Buy at Zacks Investment Research - July 5 at 12:38 PM logoBioScrip, Inc. (BIOS) Upgraded to Hold at Zacks Investment Research - July 2 at 12:02 PM



BioScrip (BIOS) Chart for Wednesday, September, 20, 2017

This page was last updated on 9/20/2017 by Staff